An interventional study of Medication review in Older Patients, Medication Review and Cross-sectional Communication, sponsored by Odense University Hospital. Completed at 2 sites in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Odense University Hospital · Not applicable, Interventional, and Health services research
In this trial, the feasibility of cooperation between clinical pharmacists and physicians by conducting a telephone follow-up conversation between the hospital geriatrician, the general practitioner and the clinical pharmacist is evaluated. During hospital stay the clinical pharmacist and the geriatrician will review older patients' medication and discuss the future treatment with the general practitioner after discharge by telephone or medico-technology.
The first part of the feasibility study will be a qualitative baseline measure of characteristics of the participants and work flow. The second part will be a pilot randomized controlled study where participants will be allocated to either usual care or medication review and follow up contact
719 studies on the registry are indexed under Communication; 159 are open to participants now.
This study's enrollment of 232 is above the median of 144 across 571 interventional studies indexed under Communication.
Browse Communication studies →Odense University Hospital is the lead sponsor of 479 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* 5 drugs or more
Exclusion Criteria:
Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.
Behavioral: Medication review
Medication history by pharmaconomist. Usual care by physicians.
Conducted by the pharmacist and discussed with hospital physician
Changes in number of medications
Increase or decrease in number of medications from admission to discharge
Time frame: At admission and at discharge
Parts of the intervention completed
In the intervention Group only, it is measured, how many of the elements of the intervention the patient actually have received
Time frame: Day 1 after discharge
Changes in the Electronic Medication Profile (FMK)
How many changes have been Applied to the Electronic Medication Profile
Time frame: 14 days after discharge
Number of readmissions
Data from registers
Time frame: within 30 days after discharge
Number of emergency visits
Data from registers
Time frame: within 30 days after discharge
Number of visits at general practitioner
Data from registers
Time frame: within 30 days after discharge
Patient satisfaction with the discharge
Measured by telephone interview
Time frame: 14 days after discharge
Changes in patient-experienced quality of life
Measured by telephone interview using the 5-item questionnaire EQ-5D, where each question can be answered on a 5-point Likert Scale ranging from "very high degree of problems" to "very low degree of problems"
Time frame: At admission and 14 days after discharge
Health care professionals satisfaction
Measured by a questionnaire
Time frame: 3 months after implementation
Plan to share: No — No IPD are planned sharing
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Nov 2018, 11 months.
Of 390 non-industry interventional studies with no phase under Communication, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's 11 months is below that.
Counting every sponsor, half of 394 studies reached it within 18 months; a quarter within 6 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.